PDCO meeting sees good news for J&J but a mix for GSK and AZ; Janssen pulls Invega app

The December 10-12, 2008, meeting of the Pediatric Committee (PDCO) of the European Medicines Agency (EMEA) saw an abundance of good news for  US health care major Johnson & Johnson, with a mix for UK-based giants  AstraZeneca and GlaxoSmithKline.

Among the opinions adopted at the meeting, the PDCO agreed pediatric  investigation plans for the following list of products:

- investigational drug apixaban, from USA-headquartered Bristol-Myers  Squibb, in the therapeutic area of cardiovascular diseases;